Evidence map›Paper›PMID 36209578›Full record

ArticleBiomaterials2022

Scalable macroporous hydrogels enhance stem cell treatment of volumetric muscle loss.

Ioannis Eugenis, Di Wu, Caroline Hu, Gladys Chiang, Ngan F Huang, Thomas A Rando

Abstract read
In one paragraph

Article in Biomaterials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Novel muscle-derived extracellular matrix hydrogel promotes angiogenesis and neurogenesis in volumetric muscle loss.Matrix biology : journal of the International Society for Matrix Biology · 2024
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ioannis EugenisDepartment of Bioengineering, Stanford University, Stanford, CA, USA; Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA.
Di WuDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA; Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA.
Caroline HuVeterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA.
Gladys ChiangVeterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA.
Ngan F HuangThe Stanford Cardiovascular Institute, Stanford University, Stanford, CA, USA; Department of Cardiothoracic Surgery, Stanford University, Stanford, CA, USA; Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA.
Thomas A RandoDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA; Paul F. Glenn Center for the Biology of Aging, Stanford University School of Medicine, Stanford, CA, USA; Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA; Broad Stem Cell Research Center, UCLA, Los Angeles, CA, USA. Electronic address: rando@stanford.edu.

Funding

Technology Development P2CHD086843 · NICHD · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI AMBROSIO, FABRISIA · 2015 to 2024
$10.5M
Engineering Vascularized Skeletal Muscle for Treatment of Volumetric Muscle LossI01BX004259 · VA · VETERANS ADMIN PALO ALTO HEALTH CARE SYS · PI Ngan F. Huang · 2019 to 2026
–
Muscle Stem Cell Therapy for Volumetric Muscle LossI01RX001222 · VA · VETERANS ADMIN PALO ALTO HEALTH CARE SYS · PI HUANG, NGAN F. · 2014 to 2023
–
BLRD VA I01 BX004259NICHD NIH HHS P2C HD086843RRD VA I01 RX001222
6 · The paper itself

Abstract

Volumetric muscle loss (VML), characterized by an irreversible loss of skeletal muscle due to trauma or surgery, is accompanied by severe functional impairment and long-term disability. Tissue engineering strategies combining stem cells and biomaterials hold great promise for skeletal muscle regeneration. However, scaffolds, including decellularized extracellular matrix (dECM), hydrogels, and electrospun fibers, used for VML applications generally lack macroporosity. As a result, the scaffolds used typically delay host cell infiltration, transplanted cell proliferation, and new tissue formation. To overcome these limitations, we engineered a macroporous dECM-methacrylate (dECM-MA) hydrogel, which we will refer to as a dECM-MA sponge, and investigated its therapeutic potential in vivo. Our results demonstrate that dECM-MA sponges promoted early cellularization, endothelialization, and establishment of a pro-regenerative immune microenvironment in a mouse VML model. In addition, dECM-MA sponges enhanced the proliferation of transplanted primary muscle stem cells, muscle tissue regeneration, and functional recovery four weeks after implantation. Finally, we investigated the scale-up potential of our scaffolds using a rat VML model and found that dECM-MA sponges significantly improved transplanted cell proliferation and muscle regeneration compared to conventional dECM scaffolds. Together, these results validate macroporous hydrogels as novel scaffolds for VML treatment and skeletal muscle regeneration.

Indexed as

HydrogelsTissue EngineeringAnimalsExtracellular MatrixMiceMuscle, SkeletalMyoblastsRatsStem CellsTissue ScaffoldsHydrogelsMacroporositySatellite cellsScaffoldSkeletal muscleStem cellsTissue engineeringVolumetric muscle loss

Identifiers

PMID36209578
PMCPMC10267099

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.